SPRB Stock: Spruce Biosciences, Inc. Stock Price, Analysis & Insights
Get live sprb stock price $12.50, comprehensive Spruce Biosciences, Inc. stock analysis, charts, news, and expert forecast. Real-time sprb stock data and investment insights.
Company Overview
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Company Information
- CEO
- Javier Szwarcberg
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
Contact Information
- Address
- 2001 Junipero Serra Boulevard
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 7.04M market capitalization
- Trading Volume: 45.94K shares traded today
- Price Range: 52-week range of $7.00 - $3420.00
- Exchange: Listed on NASDAQ
Financial Metrics
Market Analysis for Spruce Biosciences, Inc.
Spruce Biosciences, Inc. (SPRB) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 7.04M, the company represents a significant player in its market. The stock is currently trading at $12.50 with a positivedaily change of 40.45%.
The company's 20 employee base and presence on the NASDAQexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.13, beta of 2.43, and 52-week price range from $7.00 to $3420.00when evaluating investment opportunities.
Why Invest in Spruce Biosciences, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ)
- • Experienced leadership under Javier Szwarcberg
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.